Welcome to our dedicated page for Amrize SEC filings (Ticker: AMRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amrize Ltd (NYSE: AMRZ) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Switzerland-incorporated issuer listed on the New York Stock Exchange and the SIX Swiss Exchange, Amrize files reports with the U.S. Securities and Exchange Commission that give investors structured information about its operations and financial condition.
Recent Form 8-K filings from Amrize have reported quarterly financial results and related investor materials. These filings typically reference earnings press releases and investor presentations that discuss revenue by segment, non-GAAP metrics such as Adjusted EBITDA, Free Cash Flow, Net Debt and Net Leverage Ratio, and commentary on the performance of the Building Materials and Building Envelope segments. They also confirm details such as the company’s jurisdiction of incorporation in Switzerland and its principal executive office location in Zug.
On this page, investors can monitor new 8-K filings as they are released, along with other SEC forms when available, such as annual and quarterly reports that provide more comprehensive detail on Amrize’s business, risk factors and segment information. Filings related to capital structure, such as debt issuance, and any documents reporting significant events or transactions, are also part of the regulatory record.
Stock Titan enhances these filings with AI-powered summaries designed to explain the main points of lengthy documents in clear language. This can help readers quickly understand key topics such as segment performance, changes in leverage, major investments, or strategic initiatives like the ASPIRE program, while still allowing direct access to the full original filings for detailed analysis.
James J. Gosa, who is identified as an officer (President, Building Envelope) and a director of Amrize Ltd (AMRZ), was awarded restricted stock units on 08/11/2025 under the Amrize Ltd 2025 Omnibus Incentive Plan. Two awards were reported: 36,952 RSUs that vest on March 21, 2026 and 18,687 RSUs that vest on March 21, 2027. Both grants are recorded with a price of $0.
Following these reported transactions the filing shows the reporting person beneficially owns 55,639 ordinary shares on a direct basis. The entries are presented as non-derivative security acquisitions (restricted stock unit awards) with the vesting schedule and award source explicitly stated in the explanations.
Poletti Samuel Jonas, identified as Chief Strategy & M&A Officer of Amrize Ltd (AMRZ), reported a purchase of ordinary shares on 08/08/2025. The filing shows an acquisition of 1,280 ordinary shares purchased at CHF 37.37 per share, converted at the transaction-date rate (USD 1.00 = CHF 0.8086) to a reported price of $46.22 per share. Following the transaction, the reporting person beneficially owned 3,389 ordinary shares in a direct ownership form.
The Form 4 was submitted by one reporting person and bears a signature dated 08/12/2025 by Hans Weinburger, Attorney-in-Fact. The filing explicitly discloses the currency conversion used for the transaction. No derivative transactions or additional dispositions are reported in this Form 4.
Mario Gross, Chief Supply Chain Officer of Amrize Ltd (AMRZ), reported two open-market purchases of ordinary shares. The filings show purchases of 5,000 shares on 08/08/2025 and 2,600 shares on 08/11/2025, executed in Swiss francs and converted to U.S. dollars at the stated exchange rates. The reported USD-equivalent prices were $46.78 and $47.75 per share. After these transactions Gross beneficially owned 20,232 shares. The Form 4 discloses the transaction codes as purchases and includes conversion details for transparency.
The filing contains only non-derivative purchases and a manual signature by an attorney-in-fact; no options, dispositions, or other compensatory awards are reported.
Amrize Ltd (AMRZ) reporting person Roald Brouwer, identified as Chief Technology Officer and director, purchased ordinary shares across three dates in August 2025. The Form 4 shows purchases of 1,000 shares on 08/08/2025 at $46.25, 1,000 shares on 08/11/2025 (782 at $48.08 and 218 at $48.07), and 1,000 shares on 08/12/2025 at $46.84, bringing his beneficial ownership to 3,000 shares following these transactions. The filing discloses that each purchase was executed in Swiss francs and converted to U.S. dollars using transaction-date exchange rates provided for each trade.
The report is limited to equity purchases and shows no derivative transactions. All amounts and conversion notes are presented on the Form 4; no additional financial results or company-level context are included in this filing.
Denise R. Singleton, listed as Chief Legal Officer & Corp Sec of Amrize Ltd (AMRZ), filed a Form 4 reporting a change in beneficial ownership on 08/08/2025. The filing shows 4,000 ordinary shares associated with a transaction code “P” and a price of $47.64. The Form 4 was signed by Hans Weinburger as attorney-in-fact on 08/11/2025. The filing lists the reporting person as an officer and was filed by one reporting person.
Ian A. Johnston, identified as Chief Financial Officer, executed multiple purchases totaling 10,500 ordinary shares of Amrize Ltd on 08/08/2025 at prices between $47.66 and $47.75 per share. The reported transactions raised his beneficial ownership to 17,344 ordinary shares. The Form 4 lists only non-derivative purchases in separate lots and shows no derivative holdings reported.
UBS Group AG, through its UBS Asset Management division, reports beneficial ownership of 38,197,652 ordinary shares of Amrize Ltd, representing 6.74% of the class. UBS Asset Management reports sole voting power over 35,252,775 shares and shared dispositive power over 38,197,652 shares, indicating voting control for most of its reported position.
The filing identifies UBS Asset Management (Americas) LLC and multiple UBS AM affiliates as included in the disclosure and states accounts are managed on a discretionary basis with rights to dividends or sale proceeds. The filer certifies the holdings were acquired in the ordinary course of business and were not acquired to change or influence control of the issuer.
Thomas Schmidheiny and affiliated entities disclosed a significant 6.671% ownership stake in Amrize through a Schedule 13D filing. The position was acquired following Amrize's spin-off from Holcim on June 23, 2025.
Key ownership details:
- Total beneficial ownership of 37,818,703 ordinary shares
- Schweizerische Cement-Industrie-Aktiengesellschaft (SCIA) holds 37,111,376 shares (6.547%)
- Cimcap AG holds 678,450 shares (0.120%)
- Shares received as dividend-in-kind through Holcim's distribution
The spin-off separated Amrize's North American operations (US, Canada, Jamaica) from Holcim's global business. The reporting persons, all Swiss entities, have not disclosed specific plans regarding their investment but maintain the right to acquire additional shares or sell their position based on ongoing evaluation of business conditions and opportunities.